Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-based compensation expense included in condensed consolidated statements of income

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:

	For the Three Months Ended March 31,
(In millions)	2024		2023
Research and development	$	27.4	$	31.3
Selling, general and administrative	44.0		50.1
Subtotal	71.4		81.4
Capitalized share-based compensation costs	(3.3)		(3.3)
Share-based compensation expense included in total cost and expense	68.1		78.1
Income tax effect	(12.9)		(14.7)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	55.2	$	63.4

Summary of share-based compensation expense associated with each of our share-based compensating programs

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:

	For the Three Months Ended March 31,
(In millions)	2024		2023
Time-vested restricted stock units	$	57.3	$	61.7
Performance stock units settled in stock	10.5		9.5
Employee stock purchase plan	4.5		4.7
Performance stock units settled in cash	(2.1)		2.5
Stock options	0.9		0.8
Market stock units	0.3		2.2
Subtotal	71.4		81.4
Capitalized share-based compensation costs	(3.3)		(3.3)
Share-based compensation expense included in total cost and expense	$	68.1	$	78.1